GBS

Twin Hong Kong International Jewellery Shows Open Today as a New Round of Trade Fairs since Return to Normalcy

Retrieved on: 
Wednesday, March 1, 2023
Diamond, GBS, HKTDC, Social media, Convention center, Gold, Hong Kong Trade Development Council Trade Fairs, Administration, Lightning Ridge, New South Wales, Hong Kong Trade Development Council, Touring Exhibitions Group, JP, London Organising Committee of the Olympic and Paralympic Games, Hall, Jaipur Jewellery Show, Treasure, Jewellery, Fair, Hon, Film industry, Nature, Ammolite

The 39th Hong Kong International Jewellery Show and the 9th Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council, open today at the Hong Kong Convention and Exhibition Centre in Wan Chai.

Key Points: 
  • The 39th Hong Kong International Jewellery Show and the 9th Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council, open today at the Hong Kong Convention and Exhibition Centre in Wan Chai.
  • The Hong Kong International Diamond, Gem & Pearl Show offers a wide range of raw materials for jewellery and treasures
    The 39th Hong Kong International Jewellery Show and the 9th Hong Kong International Diamond, Gem & Pearl Show, organised by the Hong Kong Trade Development Council (HKTDC), are the first major trade fairs being held at the Hong Kong Convention and Exhibition Centre in Wan Chai after the territory returns to normalcy.
  • Exhibitors value the first trade fairs after the pandemic and bring a wide range of valuable and unique jewellery items to both shows.
  • - Hong Kong International Jewellery Show: https://www.hktdc.com/event/hkjewellery/en
    - Hong Kong International Diamond, Gem & Pearl Show: https://www.hktdc.com/event/hkdgp/en

HKTDC takes Building for the Future campaign to Indonesia

Retrieved on: 
Tuesday, February 28, 2023
GBS, US, HKTDC, Sino Group, Ministry, Housing, Legislative council, Hong Kong Trade Development Council, Public works, MH, Future, Engineering, Architecture, Republic, Functional constituency, JP, Government, Directorate, Nusantara Capital City Authority, City, MVA, Building for the Future, HPA, Forum, Property management, Creative industries, Tutoring, IRES, LL.M

The "Building for the Future" promotion was held in Indonesia for the first time, with the highlighted "Hong Kong Forum on Urban Development" attracting more than 300 representatives from Indonesian government departments and businesses.

Key Points: 
  • The "Building for the Future" promotion was held in Indonesia for the first time, with the highlighted "Hong Kong Forum on Urban Development" attracting more than 300 representatives from Indonesian government departments and businesses.
  • Dr Ir Herry Trisa Putra Zuna, Directorate General of Ministry of Public Works and Housing, Republic of Indonesia, gave remarks at the Forum.
  • It introduced the strengths and value-added services of Hong Kong IRES and explored collaboration opportunities between Indonesia and Hong Kong in infrastructure development projects.
  • Since the launch of the Building for the Future campaign in 2015, the HKTDC has led Hong Kong urban development services missions to eight cities in Mainland China and Kuala Lumpur, Malaysia.

QYOU CEO and Co-Founder Curt Marvis to Present Plenary Presentation at The Times of India Global Business Summit

Retrieved on: 
Friday, February 17, 2023
The Times Group, Entrepreneurship, Friends, The Times, Intellectual, Change, GBS, The Times of India, Economy, LOS

TORONTO, LOS ANGELES and DELHI, Feb. 17, 2023 /PRNewswire/ - QYOU Media Inc. (TSXV: QYOU) (OTCQB: QYOUF), announced today that its CEO and Co-Founder, Curt Marvis, has been invited to present a plenary presentation at the Economic Times 2023 Global Business Summit taking place in Delhi, India on February 17th and 18th.

Key Points: 
  • TORONTO, LOS ANGELES and DELHI, Feb. 17, 2023 /PRNewswire/ - QYOU Media Inc. (TSXV: QYOU) (OTCQB: QYOUF), announced today that its CEO and Co-Founder, Curt Marvis, has been invited to present a plenary presentation at the Economic Times 2023 Global Business Summit taking place in Delhi, India on February 17th and 18th.
  • The presentation is part of the two day summit featuring many of Asia's largest business leaders.
  • The aim of the Global Business Summit (GBS), as always, remains "Scripting Economic Change" and with this objective, they are bringing together an amalgamation of change drivers in New Delhi to deliberate on "Resilience, Influence, Dominance".
  • Curt Marvis remarked on the event, "I am honored to have been invited by our good friends at The Times of India Group to speak before such an elite group of business and thought leaders.

Twelve mutual funds and ETFs managed by TD Asset Management Inc. recognized at the Fundata FundGrade A+® Awards

Retrieved on: 
Friday, January 27, 2023
Canada Deposit Insurance Corporation, Toronto-Dominion Bank, GBS, TD, Solactive, GPA, Government, ETF, FTSE Global Equity Index Series, Funding, Equity, CAD, Fundata, Information ratio, Investment, Prospectus, Financial adviser, Holding company, Issuer, Index

The annual FundGrade A+® Awards are presented by Fundata Canada Inc. to recognize the "best of the best" among Canadian investment funds.

Key Points: 
  • The annual FundGrade A+® Awards are presented by Fundata Canada Inc. to recognize the "best of the best" among Canadian investment funds.
  • TD Mutual Funds and the TD Managed Assets Program portfolios are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto-Dominion Bank, and are available through authorized dealers.
  • TD ETFs are managed by TD Asset Management Inc., a wholly-owned subsidiary of The Toronto- Dominion Bank.
  • TD Asset Management Inc. ("TDAM"), a member of TD Bank Group, is a North American investment management firm.

BioBam Announces at PAG30 the Latest Version of OmicsBox 3 With Its New Genetic Variation Module

Retrieved on: 
Tuesday, January 17, 2023
Software, Research, Pharmaceutical, Data Management, Technology, Genetics, Health Technology, Science, Biotechnology, Other Technology, Other Science, Health, GWAS, Disease, BioBam Bioinformatics, WGS, GBS, Conference, Website, International Plant Nutrition Colloquium, Genetic variation, Multimedia, Agriculture

BioBam launches the latest version of its bioinformatics software OmicsBox 3.0, with the new genetic variation module to be exhibited at the International Plant and Animal Genome Conference.

Key Points: 
  • BioBam launches the latest version of its bioinformatics software OmicsBox 3.0, with the new genetic variation module to be exhibited at the International Plant and Animal Genome Conference.
  • View the full release here: https://www.businesswire.com/news/home/20230117005565/en/
    BioBam will showcase its latest advancement at the largest AG-Genomics meeting in the world.
  • The main highlight of OmicsBox version 3.0 is its new Genetic Variation Module which allows for performing variant calling, filtering, and annotation, as well as associating genetic variations with a particular trait or disease via genome-wide association studies.
  • More details about the novel Genetic Variation module can be found here: BioBam's Website

Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises

Retrieved on: 
Sunday, January 8, 2023
Well, Severe cognitive impairment, SAD, Autoimmune disease, Complement component 1q, Autoimmune hemolytic anemia, Disease, Growth, LN, Plasma, Medicine, Neurodegeneration, Investment, The First Half of My Life, GA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Brain, HIV disease progression rates, Lupus nephritis, HD, Nephritis, AFL, Physician, Eye, Pivotal trial, FDA, Autoimmunity, Geographic atrophy, GBS, Anemia, Food, ALS, Continuous Progress Mathematics, Time-invariant system, Therapy, Webcast, Nerve, Hemolysis, CAD, MAD, Multifocal motor neuropathy, Cold agglutinin disease, Nerve Damage, Patient, Ophthalmology, MMN, Conference, Pharmaceutical industry, Waiha, Amyotrophic lateral sclerosis

BRISBANE, Calif., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today reported progress across its broad portfolio of complement therapies and outlined its focus on four flagship programs to support its advancement to a late-stage biopharmaceutical company developing first-in-class treatments for complement-mediated diseases of the body, brain and eye.

Key Points: 
  • Annexon has prioritized resources and execution of late-stage development of its four flagship programs: Guillain-Barré syndrome (GBS), Huntington’s disease (HD), geographic atrophy (GA) and its first-in-kind oral small molecule, ANX1502.
  • Our mission is to free the body, brain and eye from diseases driven by the classical complement cascade,” said Douglas Love, president and CEO of Annexon.
  • Following an assessment of the market opportunity in wAIHA and a range of additional autoimmune indications, Annexon has determined not to advance development in wAIHA.
  • A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

Everest Group Survey Points to a Resilient Year for Outsourcing in 2023 as Global Enterprises Prioritize Cost Savings, Talent Management

Retrieved on: 
Thursday, January 5, 2023
BPS, ESG, GBS, Automation, IBM Global Services, Research, Secure key issuing cryptography, Organization, Face, Growth, AI, AR, Blockchain, Investment, Internet, ITS, Workload, Tree, RPA, Risk management, Creative industries, DALLAS

DALLAS, Jan. 5, 2023 /PRNewswire-PRWeb/ -- In the face of macroeconomic uncertainty, the majority of enterprises feel cautiously optimistic about 2023 and expect to tap outsourcing resources to control costs and meet the demand for talent, according to the results of Everest Group's annual Key Issues survey. In fact, more than 80% of respondents expect their investments in outsourcing for IT services (ITS) and business process services (BPS) to stay the same or increase in 2023 over 2022, and more than 40% are optimistic about growth in their global services budgets in the coming year.

Key Points: 
  • Global leaders share their chief concerns and strategy adjustments for outsourcing in 2023 in Everest Group's annual Key Issues survey.
  • Everest Group's 2023 Key Issues Study comprises the input of 200 global leaders across enterprises, Global Business Services (GBS) centers and service providers.
  • Everest Group delivered the key findings from this research in a December 13 webinar, "Rise Above Economic Uncertainty and Succeed."
  • Asked to rank their top-of-mind issues for 2023, enterprises cited "price and cost pressures" as number one this year, moving into the top position from second place last year.

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Retrieved on: 
Thursday, January 5, 2023
Communication, Boehringer Ingelheim, GBS, Food, European Medicines Agency, Drug development, III, Streptococcus, Drug, Ghent University, Streptococcus agalactiae, GSK, Risk, Disease, Development, Influenza, Pregnancy, US Food Sovereignty Alliance, Safety, FDA, Senior, Marketing, Fast Track, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.
  • Lidia Oostvogels brings a wealth of experience in vaccine development with more than 25 years' experience in clinical development.
  • Oostvogels' experience will be instrumental as MinervaX progresses its GBS vaccine towards phase III clinical development.
  • Lidia Oostvogels, Chief Medical Officer of MinervaX, said: "I am hugely excited to join MinervaX and look forward to contributing to the further development of its GBS vaccine.

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Retrieved on: 
Thursday, January 5, 2023
Communication, Boehringer Ingelheim, GBS, Food, European Medicines Agency, Drug development, III, Streptococcus, Drug, Ghent University, Streptococcus agalactiae, GSK, Risk, Disease, Development, Influenza, Pregnancy, US Food Sovereignty Alliance, Safety, FDA, Senior, Marketing, Fast Track, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine.
  • Lidia Oostvogels brings a wealth of experience in vaccine development with more than 25 years' experience in clinical development.
  • Oostvogels' experience will be instrumental as MinervaX progresses its GBS vaccine towards phase III clinical development.
  • Lidia Oostvogels, Chief Medical Officer of MinervaX, said: "I am hugely excited to join MinervaX and look forward to contributing to the further development of its GBS vaccine.

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

Retrieved on: 
Monday, December 12, 2022
Good manufacturing practice, Michigan State University, Lighthouse, Parkinson's disease, Depression, Clinical trial, Research, Nature, Security (finance), Chronic pain, National Research Council, National Research Council Canada, Hospital, GBLX, Cytokine release syndrome, NRC, University, OTCQB, Kava, Scale, Attention, Patient, Anxiety, GBS, Pharmaceutical industry

LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic.

Key Points: 
  • LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences , Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic.
  • Approximately 300 million people in the world suffer from anxiety and depression, while effective clinical treatments are still limited globally.
  • Gb Sciences has leveraged its AI-enabled drug discovery technology to develop kava plant-inspired treatments for anxiety and depression that are designed to enhance mood but are non-psychedelic.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada.